Monepantel is under clinical development by PharmAust and currently in Phase II for Motor Neuron Diseases. According to GlobalData, Phase II drugs for Motor Neuron Diseases have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Monepantel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monepantel overview
Monepantel is under development for the treatment of amyotrophic lateral sclerosis (ALS), motor neuron diseases, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), unspecified cancer and neurodegenerative disorders. The drug candidate is administered through oral route in the form of tablet. It acts by targeting p70S6K (70-kDa Ribosomal Protein S6 Kinase) and mTOR.
The drug candidate was under development for the treatment of ovarian cancer and refractory solid tumors.
PharmAust overview
PharmAust (PAA) is a clinical-stage biotechnology company that develops new therapeutics for human and animal health applications. The company’s lead product candidate monepantel (MPL) is a potent small molecule and oral aminoacetonitrile compound that inhibits the mammalian target of the rapamycin (mTOR) pathway in cell growth and proliferation of cancer cells that treat canine B-cell lymphoma, cancers in dogs and motor neuron disease (MND), amyotrophic lateral sclerosis (ALS) in humans. PAA is headquartered in South Melbourne, Victoria, Australia.
For a complete picture of Monepantel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
